Lynparza (olaparib) showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer, according to long-term data.
Newly released results from the phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.
FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer.
FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
FDA has approved Imfinzi (durvalumab), in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer.
AstraZeneca will acquire TeneoTwo Inc., including its phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
AstraZeneca has launched the global R&D Postdoctoral Challenge to help accelerate the treatment of complex diseases, including cancer.
